MapLight Therapeutics, Inc. (MPLT) Financial Statements
Free cash flow over the same period: -$175.1M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MPLTMapLight Therapeutics, Inc.Follow MPLT — free
—
Price chart with a free account
- Market cap
- 369.6M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 1 Dec, in 38 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Research & development | 68.5 | 138.3 | 198.8 | |
| Operating income | -82.9 | -169.1 | -242.9 | |
| Pre-tax income | -77.6 | -161.2 | -229.8 | |
| Net income | -77.6 | -161.2 | -229.8 | |
| Diluted EPS ($) | -105.38 | -18.56 | -5.05 | |
| Diluted shares (mn) | 0.7 | 8.7 | — |
USD millions · SEC XBRL
MapLight Therapeutics, Inc. — questions
- What is MapLight Therapeutics, Inc.'s net income?
- -$229.8M over the twelve months to 2026-06-30.
- What is MapLight Therapeutics, Inc.'s free cash flow?
- -$175.1M over the twelve months to 2026-06-30.
- What are MapLight Therapeutics, Inc.'s diluted earnings per share?
- $-5.05 over the twelve months to 2026-06-30.
Every figure on this page comes from MapLight Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.